Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03989115
Title Dose-Escalation/Expansion of RMC-4630 and Cobimetinib in Relapsed/Refractory Solid Tumors and RMC-4630 and Osimertinib in EGFR Positive Locally Advanced/Metastatic NSCLC
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors Revolution Medicines, Inc.

Advanced Solid Tumor

lung non-small cell carcinoma


Cobimetinib + RMC-4630

Osimertinib + RMC-4630

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST